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CONTROL DESIGN OF AN HIV-1 MODEL
Amel Rahmoun, Djamila Benmerzouk and Bedr’Eddine Ainseba
Abstract. In this paper, we formulate a dynamic mathematical
model that describes the interaction of the immune system with the hu-
man immunodeficiency virus (HIV), combined with nonlinear continuous
feedback control. The detailed computations of two linearizing inputs is
presented. It results in the design of a first fully linearizable system and a
second partially linearizable one. The proposed controllers have the ability
to drive the system close to the healthy equilibrium state. Numerical simu-
lations demonstrate them effectiveness by maintaining virus concentration
in very low levels and healthy cells in satisfactory levels.
1. Introduction
Since the human immunodeficiency virus (HIV), the virus that causes ac-
quired immune deficiency syndrome (AIDS), was first identified in the United
States more than 35 years ago, expanded treatment options have brought
down death rates, increased patient adherence, improved the quality of life
for patients and paved the way for future research focused on preventing the
disease.
Nowadays, there are 52 medicines and vaccines for HIV currently in devel-
opment, including additional combination treatments, more effective therapies
and preventative vaccines [26]. Among the 52 medicines in development for
HIV, there are 32 antiretrovirals and antivirals, 16 vaccines and 4 cell thera-
pies including a potential first-in-class medicine intended to prevent HIV from
attaching to new cells and breaking through the cell membrane [26].
In this frame, mathematical models attempt to describe viral replication
dynamics and virus-specific immune responses of HIV-AIDS infection. Most
of them are proposed in an abstract sense, involving nonlinear ordinary differ-
ential equations [15,19]. They suggest different possibilities in which the body
interacts with the pathogen, the most basic of these models typically include
three of the key dynamic comportments: uninfected target cells, infected cells
2020 Mathematics Subject Classification. 92B99, 93C10, 93D15, 16W25, 37M05.
Key words and phrases. Mathematical biology, nonlinear systems, stabilization of sys-
tems by feedback, Lie derivatives, simulations.
131
132 A. RAHMOUN, D. BENMERZOUK AND B. AINSEBA
and virus. We refer the reader to [1, 20, 25] for an extensive survey on the
collection of mathematical models used to analyze HIV infection.
If the range of model parameters for a population is such that dramat-
ically different outcomes are predicted for different individuals, bifurcation
values for different parameters could suggest target interventions for contin-
ued successful treatment. In [22], Lyapunov-Schmidt reduction method is
used to investigate topological bifurcation when varying the force of infection
parameter. In [27], a study on the global stability and Hopf bifurcation of an
HIV-1 infection model with saturation incidence is proposed and in [28] the
global properties and bifurcation analysis of an HIV-1 infection model with
two target cells is proposed.
On the other hand, many control strategies have been used in litera-
ture to design epidemic control programs [6, 23]. Various objective criteria
are adopted and produce valuable theoretical results. One can find a good
summary of the different methods of optimal control that may be applied to
disease models in [13] and for HIV in [8]. In [4], authors describe a contin-
uous differential equation model of the HIV-1 interaction with the body and
could use external feedback stabilizing controls. A technique to control virus
concentration for HIV-1 infection model obtained from actual patients data is
introduced in [2], the strategy is based on Linear quadratic regulator (LQR).
Interesting work was done in [14] on the optimal control of HIV chemother-
apy. In [21], an application of Pontryagin maximum principle to compute
the optimal control under quadratic cost for an HIV-1 within host model was
performed. A realistic dosage regimen was designed in [17] which drives the
immunological system close to the healthy equilibrium state.
In this work, a three dimensional nonlinear HIV-1 within host model is
considered, two controls representing possible treatments are incorporated.
We then develop a feedback linearization for this controlled model. The aim
is to cancel existing nonlinearities by algebraically transforming the nonlinear
model into an equivalent system of a linear form. That way, linear control
techniques can be applied.
In this frame, according to dynamic feedback linearization theory, two
cases may occur, the system can be fully feedback linearized or only partially
feedback linearized depending on the value of its relative degree. In the lat-
ter case, the total dynamics of the system can be divided into an external
controlled part and an internal unobserved uncontrolled part.
The inputs considered in our model give rise to both cases. We then con-
struct an appropriate coordinate transformation for each case that is chosen
to be a diffeomorphism. After this, simulations are performed to illustrate
the control action.
This paper is organized as follows: in section 2, a description of the consid-
ered mathematical model is given, as well as the incorporation of two different
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controls representing possible treatments. In section 3, the detailed lineariza-
tion, analyze and control feedback design are presented for both adopted
controls and in section 4, numerical simulations are given to highlight the
pertinence of the obtained results. Conclusion and perspective are given in
section 5, whereas some recalls and detailed calculus are given in the Annex.
2. Model description and problem statement
Once the infection by HIV occurs, the virus gets attached to a CD4+
T-cell and gets into its interior, then changes its RNA to DNA. This occurs
thanks to Reverse Transcriptase enzyme which is furnished by the virus itself
[15]. This new DNA gets inserted into the host cell DNA. It is then considered
by the CD4+ host cell as a normal set of genes, that is why the fouled cell
produces thousands of copies of the virus different Proteins. After a very
complex process, Protease enzyme helps those proteins gathering together to
form complete virus, that are released by the mother cell [15].
Although the mechanism for T-cells proliferation is largely unknown, most
models in HIV-1 literature exhibit a constant source term that represents
the number of CD4+ T-cells population in the thymus, that is decreased
by their natural death, so in those models, healthy cells dynamics (with no
interaction with virus or infected cells) are governed by an equation of the
form: Ṡ = δ − αS [19]. A logistic term to this equation is added in [20]
to represent mitosis multiply when stimulated by antigen or mitogen, which
resulted in an equation of the form: Ṡ = δ−αS+ bS(1− SK ). In [25], authors
had taken into account infected cells concentration as well in the logistic term,
which gave the equation: Ṡ = δ − αS + bS(1− S+IK ).
Based on the 3-Dimensional model considered by A. Perelson in [20], we
consider the following system, where healthy cells evolve according to a simple








İ(t) = −cI(t) + βS(t)V (t)
V̇ (t) = −dV (t) + rcI(t)
S(0) = S0, I(0) = I0, V (0) = V0
Where S(·) denotes susceptible exposed (not yet infected) CD4+ T-cells
concentration at time t, t ∈ [0, T ] T > 0; I(·) denotes infected CD4+ T-cells
density and V (·) represents circulating free virus quantity in blood at the
same time.
b is the healthy cells reproduction rate, K is the system’s carrying capac-
ity, β is a constant rate at which a healthy cell meets a free virus and becomes
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infected, also called the force of infection; c, d are the clearance rates of in-
fected cells and virus respectively; r is the number of infective virus released
by an infected cell over its life span.
Our model has a biological sense if its solution is positive at every moment
t, we thus consider the domain of definition of (S) as the positive cone:
Table 1. Model (S) parameters and initial conditions.
Parameter Significance Value Unit Ref.
b Healthy cells reproduction rate 10 mm3/day [8]
K Carrying capacity of the system 103 /mm3 estim.
c Death rate of infected cells 0.24 /day [8]
β Force of infection 2.4×10−5 mm3/day [8]
d Clearance rate of virus 2.4 /day [15]
r New infective virus 3000 /day [15]
S0 Healthy cells initial condition 1000 /mm3 [15]
I0 Infected cells initial condition 10 /mm3 [15]
V0 Virus initial condition 100 /mm3 [15]
According to [21], model (S) has three possible equilibriums:
1) The trivial equilibrium E0 = (0, 0, 0). It corresponds to the extinction
of all kinds of cells (healthy, infected, and virus).
2) The healthy equilibrium E1 = (K, 0, 0). It corresponds to a healthy
body with no infection.
3) A third positive equilibrium that exists if (and only if) rβK
d
> 1,
and is given by E∗ = (S∗, I∗, V ∗) where:
S∗ = d
rβ









We call this point the "chronic equilibrium", it represents the coexistence of
healthy and infected cells as well as free virus in blood.
Now, to suggest treatment strategies, we will incorporate the action of
two inputs ui(·), i = 1, 2 to our model (S).
The first control aims to boost the immune system. A treatment by
Interleukin 2 (IL-2) is then the perfect candidate [23], recall that IL-2 is
a naturally-occurring cytokine that can also be made artificially and a real
hope with regard to clinical trials, that shown its ability to enhance the im-
mune system at different disease stages, particularly restore defective Natural
Killers1 [10]. So it is applied on the logistic term in system (S) to increase
the parameter b. One gets the first controlled model:
1Natural Killer Cells are a type of cytotoxic lymphocyte critical to the innate immune
system, that provide rapid responses to virally infected cells.







(1 + u1(t))− βS(t)V (t)
İ(t) = −cI(t) + βS(t)V (t)
V̇ (t) = rcI(t)− dV (t)
S(0) = S0, I(0) = I0, V (0) = V0
The second control is employed to compromise viral entry into the host
cell, which is the first step of infection. It is applied on the term βSV in
system (S) to reduce the parameter β. It could be an entry inhibitor or
another type of treatment like the infusion of autologous CD4+ T cells in
which the CCR5 gene was rendered permanently dysfunctional2 as proved in
[16, 24]. It could also be the regular use of microbicide gel3 that can block
infection by the AIDS virus as showed in [7]. CXCL4 protein that directly
binds to the virus and prevents HIV from entering human host cell may also
be prescribed, see [3] for more details. It could be also the use of a compound
of cannabis, known to slow down the disease in advance states of AIDS as
demonstrated in [5].







− βS(t)V (t)(1− u2(t))
İ(t) = −cI(t) + βS(t)V (t)(1− u2(t))
V̇ (t) = rcI(t)− dV (t)
S(0) = S0, I(0) = I0, V (0) = V0
Our aim is to compute a linearizing input, using sweetble poles placement to
linearize models (S1,2), then a controller design will guarantee the decrease
of viral load by at least 90% of its value within 2-8 weeks of treatment. That
way, healthy CD4+ T-cells count will significantly increase according to [6].
3. Control design analysis
In [17], authors considered a basic HIV model where healthy cells dynam-
ics are represented by a source term decreased by the conversion to infected
cells. They incorporated two inputs and demonstrated (based on real clinical
data) that this modified system may be approximated by a single input one.
The resulting control aimed to reduce the number of free virus circulating in
the blood and was therefore applied in the third equation. In what follows, we
investigate the case of the first control noted u1 (as a CD4+ T-cells booster),
then the case of the second control noted u2 (as an entry inhibitor). Remark
that our model is slightly different from the one in [17], since it involves a
logistic function.
2CCR5 is the major coreceptor for human immunodeficiency virus.
3Still in experimentation for human use, gave interesting results on simians.
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As the control design requires a preliminary and a mandatory test of
accessibility of the system, let us first analyze this property for both controlled
models (S1,2).
3.1. Analyzing accessibility of systems (S1,2). Put x = (S, I, V ) and
f(x) =
 bS (1− SK )− βSV−cI + βSV
rcI − dV
 , g1(x) =






 , h(x) = V.
The choice of V as an output is justified by the fact that in HIV infection,
a practical data one can measure to evaluate the disease progression is the
viral load.
So, one has






[f, g2] = βSV





 bS (1− SK )− βSV bS (1− SK ) (bβSV ) SK−cI + βSV 0 (bβSV ) ( SK − 1)




 bS (1− SK )− βSV−cI + βSV
rcI − dV
















0 (βSV ) rc

Since the dynamics as well as all the parameters of model (Sc) are nonzero
and S 6= K according to [21], then {1,2 are both of rank 3. One concludes
that the models (S1,2) are both accessible in D.
3.2. Control design analysis of model (S1). Consider the SISO (Single Input,
Single Output) system (S1), where only the control u1(.), that corresponds to
the injection of IL-2 to booste the immune system is incorporated.
Detailled calculation of model’s (S1) relative degree is presented in the
annex section.
In this case, one gets r = 3, thus, this system is fully linearizable by
considering the following variables change:

























c(c+ d) + d2
]
− d3V.
In (3.2), υ is a feedback control of the following form
υ = C1Z1 + C2Z2 + C3Z3, where C1, C2, C3 ∈ R.















According to Routh-Hurwitz criteria [11], the necessary and sufficient
conditions that constants C1, C2 and C3 should verify to obtain all eigenvalues
with negative real parts are
(3.4)
{
C1, C2 and C3 < 0
C2C3 > (−C1)
Finally, the system (S1) is fully linearizable, controllable and can be stabi-
lized by any control v provided that constants Ci, i = 1, 2, 3 satisfy conditions
(3.4).
3.3. Control design analysis of model (S2). Now, consider the SISO system
(S2), where only control u2(.) that corresponds to an entry inhibitor, is incor-
porated.
Once again,the calculation of its relative degree is fully presented in the
annex section.
One has r = 2. This means that the system (S2) is partially linearizable.












To complete the coordinate change, let’s choose ϕ such that
(3.6) Lg2ϕ(x) = 0.
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Take
(3.7) ϕ(x) = S + I −K





 VrcI − dV
S + I −K
 .
It is easy to check that this coordinate change is a diffeomorphism.
Now, consider the following input:
u2(t) =




υ = C1Z1 + C2Z2, C1, C2 ∈ R(3.10)
and
L2fh(x) = rc (βSV − (c+ d)I) + d2V.































Using the Routh-Hurwitz criteria again, constants C1, C2 should be neg-
ative to ensure the stability of (3.12).






























+ c(S + I) = (c+ b)S − b
K
S2 − cK
















So this dynamics is asymptotically stable and drives the system near the
healthy equilibrium point (K,0,0).
4. Numerical simulations
4.1. The uncontrolled model. We begin by simulating the uncontrolled system
(S) to display its behavior using parameters and initial conditions of Table 1:
Figure 1
(a) The uncontrolled Model (S) global dynamics.
(b) The corresponding phase portrait.
We see stable oscillations in the dynamics of healthy and uninfected cells
as well as virus (Figure 1(a)), which gives rise to a periodic solution contained
in a stable cycle (Figure 1(b)). The outcome is that, in this situation, it
is impossible to reach the healthy equilibrium state of the model without
intervention.
4.2. The controlled model. Since any intervention is most likely to happen
when the CD4+ T-cells count is below 200mm−3, (350 or even 500mm−3,
depending on the country’s HIV treatment policy), initial conditions are con-
sidered now as S0 = 180, I0 = 750, V0 = 1e6 [26] and pole placement constants
are C1 =-0.0028, C2 =-0.045 .
1) We demonstrated in Section 3 that the system (S1) is fully linearizable.
Simulation of its implementation (3.2-3.3) gives:
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Figure 2
(a) Simulation of the partial linearization of (S1).
(b) The corresponding control.
Using this control seems to be the best way to control the overall infection
in this case, healthy cells get stabilized on high level and infected cells as
well as viruses pass to undetectable levels after a short period of treatment
(approximatively 20 days of continuous treatment). It is to be mentioned that
control u1 passes to its minimal value after almost 200 days of treatment,
and stays there for a while. After this, we remark a high rise in the dosage
of the immune system booster to maintain low levels of infected and virus
concentrations.
2) We now propose to simulate the partial linearization of system (S2)
given in (3.9-3.11).
Figure 3
(a) Simulation of the partial linearization of (S2).
(b) The corresponding control.
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After suitable pole placement, simulation shows that the viral load as well
as the number of infected cells are reduced significantly after almost 30 days
of treatment. This means that in only one month, the entry inhibitor control
law designed was successful to bring the model near the healthy equilibrium
point. We see also a significant drop in the value of the needed control after
approximatively 180 days of continuous treatment, which is not negligible
since this remedy may be cytotoxique. Unfortunately, this drop does not last
long and we remark a rise again in the control law so that it maintains the
infected cells and virus concentrations in low levels.
5. Discussion and perspectives
In this paper we have formulated a dynamic model with compartments in-
cluding healthy cells, infected cells, and virus that is subject to two treatments
as control inputs, Interleukin2 and some entry inhibitor. The uncontrolled
model possesses a locally asymptotically stable steady state and a chronic
unstable one. We then applied techniques and ideas from control theory to
derive continuous therapy protocols.
In the treatment of diseases, factors such as duration of therapy, the
amount of prescribed medication, intervals for drugs and treatment costs can
form parts of the systems control. Considering that the control models made
in most cases lead to complex nonlinearities, possibly with high dimensions,
solving them with the help of classical methods or other numerical methods
is very difficult.
When the treatment efficacy varies from no medication (0) to full med-
ication (1), a major advantage of “target tracking” approach, (the control u
is proportional to the viral load V ) is that once the virus is controlled to low
levels, the drug dosage can be reduced proportionately. Under such circum-
stances, side effects of the therapy will also be reduced.
The issue with this control approach is relating it to real drug posology.
Although several studies were performed in this area, they are not ready to be
applied yet in real life. The reason is that they do not provide a discrete-time
drug posology, but rather a continuous-time optimal control stated in terms
of abstract mathematical parameters, hardly interpreted by clinicians.
Knowing that drugs are most commonly prescribed to be taken on a fixed
dose, fixed-time interval basis, the potential success of this approach is the
periodic modification of the antiretroviral treatment regimen similar in some
ways to the infusion pump control of insulin levels in the juvenile diabetics.
Perhaps in time, this will lead to the development of a similar automated
device for this purpose.
In future work, a different approach based on hybrid controller is to be
considered and the approach used in this study will be extended to more
complex HIV-1 models.
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6. Annex
6.1. Accessibility of nonlinear dynamical systems. Consider the nonlinear sys-
tem defined by:
(6.1) ·x = f(x) + g(x)u
where x ∈ Rn, is the state of the system, u ∈ Rm, is the input to the model,
f and g, are analytic functions of appropriate dimensions.
Remember that Lie brackets between two functions f and g is denoted
by [f, g] and is given by
[f, g] = ∇g.f −∇f.g
Theorem 6.1 ([9]). If the matrix { defined by:
{ = (f, g, [f, g])
is of rank n, then the system (6.1) is accessible.
6.2. Relative degree.





fh(x) = 0 for all k < r − 1
LgL
r−1
f h(x) 6= 0
where Lfh(x) = (Oh(x))T .f(x) is the Lie derivative of h in the direction of
f .
In fact, r represents the number of times we have to differentiate the
output y to have an explicit dependence on the input u.
Remember that if the system (6.1) admits a relative degree that is equal
to r, then r ≤ n.




Φr(x) = Lr−1f h(x)
.
According to [9], there exists (n− r) functions Φj(x), r+ 1 ≤ j ≤ n, such
that ∀x ∈ D,Jac(Φ(x)) 6= 0.
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In this case, the first r components of the system can be rewritten in the














and as x(t) = Φ−1(Z(t)), putting{




Zr = b(Z) + a(Z)u(t)
In addition, according to [9], it is possible to choose the components Φj(x),
j = r + 1, ..., n such that
LgΦj(x) = 0,∀x ∈ D, j = r + 1, ..., n
then
·
Zj = qj(Z(t)) where qj(Z(t)) = LfΦj(Φ−1(Z)), j = r + 1, ..., n.














u(t) = v − b(Z)
a(Z) (knowing that a(Z) 6= 0),
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• When r = n, the same methodology applies but without the need
of functions Φj(.), j = r + 1, ..., n. We then get a fully linear and
controllable system, see [9] or [12] for further development.
6.2.1. The relative degree of the system (S1). Consider the first control











) bS (1− SK )− βSV−cI + βSV
rcI − dV














) bS (1− SK )− βSV−cI + βSV
rcI − dV

= rc (βSV − (c+ d)I) + d2V








rcβV −rc(c+ d) rcβS + d2








6= 0 (because S 6= K according to [21]).
So, one has 
Lg1h(x) = 0


















rcβV −rc(c+ d) rcβS + d2














c(c+ d) + d2
]
− d3V.
6.2.2. The relative degree of the system (S2). Considering the second con-










) bS (1− SK )− βSV−cI + βSV
rcI − dV













Lg2 (Lfh(x)) = −rcβSV 6= 0.
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Since the dynamics S and V are nonzero [21], as well as all the parameters





) bS (1− SK )− βSV−cI + βSV
rcI − dV

= rc (βSV − (c+ d)I) + d2V.
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Kontrola dizajna HIV-1 modela
Amel Rahmoun, Djamila Benmerzouk i Bedr’Eddine Ainseba
Sažetak. U ovom članku formulira se dinamički matematički
model koji opisuje interakciju imunološkoj sustava s HIV virusom,
kombiniranu s nelinearnom neprekidnom kontrolom povratne in-
formacije. Prikazani su detalji izračuna za dva linearizirana in-
puta. To je dovelo do jednog potpuno linearizabilnog sustava i
drugog djelomično linearizabilnog. Predloženi kontrolori imaju
mogućnost dovodenja sustava u blizinu zdravog ravnotežnog
stanja. Numeričke simulacije pokazuju njihovu učinkovitost
održavanjem koncentracije virusa na vrlo niskoj razini i zdravih
stanica na zadovoljavajućim razinama.
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